Fig. 6.

SeMet reduces myocardial enzymes in breast cancer patients. (a) Schematic of the participant workflow in an oral Se-enriched mushroom pilot study (ChiCTR2200056796). Six patients with breast cancer were enrolled and randomized into Se-rich oyster mushroom (SeMet 300 μg/d) and placebo groups. Peripheral blood was collected at baseline, day 2, and day 3 after the AC regimen (DOX: 60 mg/m², cyclophosphamide 600 mg/m²) administration. (b) Serum contents of peroxidized lipids on day 2 after the two cycles of the AC regimen. (c) Cardiac CK-MB, cTnT and MYO activities were measured with a highly sensitive assay (upper panels), with samples taken from the patients' four treatment cycle nodes. Representative electrocardiograph results of patients at baseline and after the fourth treatment (bottom panels). Groups were compared using the Mann‒Whitney U test (CK-MB) and Student’s t-test (cTnT, MYO activities). Data are presented as the mean ± SEM, *P < 0.05. (d) Se-rich oyster mushroom (SeMet) treatment does not affect hematological parameters. AC regimen: doxorubicin at a dose of 60 mg/m² and cyclophosphamide at a dose of 600 mg/m².